Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: Implications for Tat-mediated pathogenesis

被引:59
作者
Benelli, R
Barbero, A
Ferrini, S
Scapini, P
Cassatella, M
Bussolino, F
Tacchetti, C
Noonan, DM
Albini, A
机构
[1] Ist Nazl Ric Canc, Mol Biol Lab, Ctr Biotecnol Avanzate, I-16132 Genoa, Italy
[2] Ist Nazl Ric Canc, Tumor Progress Sect, I-16132 Genoa, Italy
[3] Ist Nazl Ric Canc, Immunopharmacol Sect, I-16132 Genoa, Italy
[4] Univ Genoa, Dept Expt Med, Anat Sect, Genoa, Italy
[5] Univ Verona, Dept Pathol, Gen Pathol Sect, I-37100 Verona, Italy
[6] Univ Turin, Inst Canc Res & Treatment, Candiolo, Italy
[7] Univ Turin, Dept Genet Biol & Biochem, Candiolo, Italy
关键词
D O I
10.1086/317597
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The extracellular activities of the human immunodeficiency virus (HIV) transactivator protein (Tat) include induction of angiogenesis and stimulation of monocyte migration, Here it is shown that polymorphonuclear leukocytes (PMNL), mostly neutrophils, rapidly invade in response to Tat in vivo and initiate the formation of new vessels, In vitro, Tat was chemotactic for PMNL and induced calcium (Ca2+) mobilization, Tat proteins with inactivating substitutions in the arginine-glycine-aspartic acid or basic domain were still active in inducing PMNL migration, whereas Tat peptides mapped the migration and Ca2+ mobilization activity to a cysteine-rich core domain, previously described as a Tat "chemokine-like" region (peptide CysL(24-51)). Tat and the CysL(24-51) peptide also induced PMNL superoxide production and the release of the angiogenic factors interleukin-X and vascular endothelial growth factor from PMNL, CysL(24-51) did not induce endothelial cell migration but was angiogenic in vivo. These data indicate that the Tat activity on PMNL is mediated by its chemokine-like region and that PMNL recruitment by Tar is linked to angiogenesis.
引用
收藏
页码:1643 / 1651
页数:9
相关论文
共 58 条
  • [51] Human Kaposi's sarcoma cell-mediated tumorigenesis in human immunodeficiency type 1 Tat-expressing transgenic mice
    Prakash, O
    Tang, ZY
    He, YE
    Ali, MS
    Coleman, R
    Gill, J
    Farr, G
    Samaniego, F
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (09): : 721 - 728
  • [52] HIV-I Tat: A polypeptide for all seasons
    Rubartelli, A
    Poggi, A
    Sitia, R
    Zocchi, MR
    [J]. IMMUNOLOGY TODAY, 1998, 19 (12): : 543 - 545
  • [53] On the detection of neutrophil-derived vascular endothelial growth factor (VEGF)
    Scapini, P
    Calzetti, F
    Cassatella, MA
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 232 (1-2) : 121 - 129
  • [54] Tosi G, 2000, EUR J IMMUNOL, V30, P1120, DOI 10.1002/(SICI)1521-4141(200004)30:4<1120::AID-IMMU1120>3.0.CO
  • [55] 2-4
  • [56] A NOVEL INTEGRIN SPECIFICITY EXEMPLIFIED BY BINDING OF THE ALPHA(V)BETA(5) INTEGRIN TO THE BASIC DOMAIN OF THE HIV TAT PROTEIN AND VITRONECTIN
    VOGEL, BE
    LEE, SJ
    HILDEBRAND, A
    CRAIG, W
    PIERSCHBACHER, MD
    WONGSTAAL, F
    RUOSLAHTI, E
    [J]. JOURNAL OF CELL BIOLOGY, 1993, 121 (02) : 461 - 468
  • [57] Dysregulation of the polymorphonuclear leukocyte - Candida spp, interaction in HIV-positive patients
    Wenisch, C
    Parschalk, B
    ZedwitzLiebenstein, K
    Graninger, W
    Rieger, A
    [J]. AIDS, 1996, 10 (09) : 983 - 987
  • [58] The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth
    Wrenger, S
    Hoffmann, T
    Faust, J
    MrestaniKlaus, C
    Brandt, W
    Neubert, K
    Kraft, M
    Olek, S
    Frank, R
    Ansorge, S
    Reinhold, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (48) : 30283 - 30288